STOCK TITAN

Vanguard (NYSE: CLB) amendment shows 0 beneficial shares after realignment

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 4 to its Schedule 13G/A reporting 0 shares of Core Laboratories Inc. common stock. The filing states Vanguard's subsidiaries underwent an internal realignment on January 12, 2026, after which certain subsidiaries report beneficial ownership separately. The amendment shows Amount beneficially owned: 0 and Percent of class: 0%. The filing is signed by Ashley Grim as Head of Global Fund Administration on 03/26/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings; this amendment reports no beneficial ownership in CLB.

The amendment records 0 shares beneficially owned and 0% of the class, reflecting reporting changes after an internal realignment on January 12, 2026. The text explains subsidiaries now report separately pursuant to SEC Release No. 34-39538.

Cash‑flow treatment and any trading activity are not disclosed in the excerpt; subsequent filings would show changes in holdings if they occur.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does the Schedule 13G/A amendment say about Vanguard's holdings in CLB?

The amendment states The Vanguard Group beneficially owns 0 shares of Core Laboratories common stock and reports 0% ownership, following an internal realignment.

Why does Vanguard report separate holdings after January 12, 2026?

Vanguard explains an internal realignment occurred on January 12, 2026, and certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538.

Who signed the filing and when was it signed?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with the signature date shown as 03/26/2026 on the amendment.

Does this filing indicate Vanguard sold shares of CLB?

The amendment only reports a current beneficial ownership of 0 shares and does not describe any specific sales, purchases, or cash consideration in the provided excerpt.

Is any other person's interest in the reported securities more than 5%?

The filing states that no one other person's interest in the securities reported is more than 5%; Vanguard notes its managed accounts have rights to dividends or proceeds as described.
Core Laboratories Inc

NYSE:CLB

View CLB Stock Overview

CLB Rankings

CLB Latest News

CLB Latest SEC Filings

CLB Stock Data

771.81M
45.44M
Oil & Gas Equipment & Services
Oil & Gas Field Services, Nec
Link
United States
HOUSTON